09.12.2012 Views

Table of Contents - WOC 2012

Table of Contents - WOC 2012

Table of Contents - WOC 2012

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

FP-RET-MO 378 (10)<br />

Correlation Between Bulbar Axis Length and Retinal Ruptures in<br />

Case <strong>of</strong> Myopia Eye<br />

Alimanovic Emina (1) , Alimanovic Ilda (1) , Pacuka Saracevic Nedžmija (1) , Al<br />

Hassan Nabil (1) , Ibiševi Mirsad (1)<br />

1. Eye Clinic, Clinical University Centar Sarajevo<br />

Objective: In this study, we analysed 180 eyes with myopia in order to<br />

determinate the ‹critical› length <strong>of</strong> bulbar axis for the occurrence <strong>of</strong> retinal<br />

ruptures as the main cause for retinal detachment.<br />

Methods: After the focused ophthalmological assessment, ultrasonic<br />

measurement <strong>of</strong> the bulbar axis length, indirect binocular ophthalmoscopy, we<br />

analysed diagnosed retinal ruptures according to the shape and axis length.<br />

Results: Mean age <strong>of</strong> our patients was between 48,43 and to 51,60 years with<br />

SD ranging from 13,88 to 18,45.The study included 102 (56,6%) male and<br />

78 (43,3%) female patients; there was no statistically significant difference<br />

regarding the occurrence <strong>of</strong> retinal ruptures between male and female patients<br />

compared to the axis length. Most dominant was round (28,2%), then oval<br />

(25%) category - multiple small ruptures (19.2%), and horseshoe-shaped<br />

(15,3%), and finally the ruptures with operculum.<br />

Conclusion: We consider the length <strong>of</strong> bulbar axis ranging from 24,52mm to<br />

26,51mm to be a predictive factor in the occurrence <strong>of</strong> retinal rupture, and later<br />

in retinal detachment. KEY WORDS: myopia, ‹critical› length <strong>of</strong> bulbar axis,<br />

retinal rupture<br />

FP-RET-MO 378 (11)<br />

Novel Developments in the Field <strong>of</strong> Silicone Oil<br />

Stappler Theodor<br />

This presentation aims to update the audience on the latest developments in<br />

the field <strong>of</strong> silicone oils. Used mostly unchanged for several decades in the<br />

treatment <strong>of</strong> complex vitreoretinal procedures, silicone oil has recently been<br />

the focus <strong>of</strong> renewed research efforts in line with an ever expanding list <strong>of</strong><br />

surgical indications. Second -generation silicone oils with improved physical<br />

properties demonstrate emulsification-resistance in- vitro as well as improved<br />

injectability, particularly when used in conjunction with modern, small-gauge,<br />

surgical instrumentation. They represent a welcome new addition to the<br />

vitreoretinal surgeon’s armory.<br />

Thyroid Eye Disease<br />

Mon 20 Feb 10:30 - 12:00 Hall 9<br />

IS-OCP-MO 379 (1)<br />

Pathophysiology <strong>of</strong> Thyroid Eye Disease<br />

Chong Kelvin (1)<br />

1. The Prince <strong>of</strong> Wales Hospital<br />

The confirmation <strong>of</strong> orbital fibroblasts as the primary target <strong>of</strong> autoimmune<br />

process, identification and reunification <strong>of</strong> two putative autoantigens:<br />

TSH receptor and IGF-1 receptors, as well as the emergence <strong>of</strong> new cell<br />

populations e.g. circulating fibrocytes and orbital adipose tissue derived stem<br />

cells and descriptions <strong>of</strong> important cellular pathways e.g. hyaluronan synthesis<br />

and adipogenesis have increased the understanding but also raised more<br />

questions towards the complex pathophysiology <strong>of</strong> this uniquely complicated<br />

yet common orbital disorder: thyroid associated orbitopathy.<br />

IS-OCP-MO 379 (2)<br />

Standardized Clinical Evaluation in Thyroid Eye Disease<br />

Von Arx George (1)<br />

<strong>WOC</strong><strong>2012</strong> Abstract Book<br />

1. ADMEDICO Orbital Centre<br />

The assessment <strong>of</strong> Graves› Orbitopathy (GO) largely relies on subjective<br />

interpretation <strong>of</strong> symptoms and signs. Nevertheless, precise measurement <strong>of</strong><br />

treatment response is mandatory for a correct interpretation <strong>of</strong> any therapeutic<br />

benefit. All clinical features <strong>of</strong> GO are derived from inflammatory and fibrous<br />

changes <strong>of</strong> orbital tissues. Standardized assessment <strong>of</strong> GO is <strong>of</strong> outstanding<br />

importance for treatment response monitoring in daily clinical practice and in<br />

designing valuable controlled trials in clinical research.<br />

IS-OCP-MO 379 (3)<br />

Medical Management <strong>of</strong> Thyroid Eye Disease<br />

Baldesch Lelio<br />

Abstract not available<br />

IS-OCP-MO 379 (4)<br />

Role <strong>of</strong> Radiotherapy in Thyroid Eye Disease<br />

Strianese Diego (1)<br />

1. University <strong>of</strong> Naples ‹Federico II›<br />

Thyroid eye disease (TED) is an autoimmune disease involving the retroocular<br />

tissues. Treatment includes immunosuppressive agents, radiotherapy,<br />

and surgery. Corticosteroids are the most widely used immunosuppressive<br />

agents for treatment <strong>of</strong> “active” phase. Recurrence <strong>of</strong> the disease after<br />

discontinuation <strong>of</strong> corticosteroid can occur. Several second-line therapies<br />

have been proposed to manage resistant TED. We present the results <strong>of</strong> a<br />

clinical trial on the efficacy <strong>of</strong> radiotherapy in patients with recalcitrant TED<br />

after discontinuation <strong>of</strong> high doses <strong>of</strong> corticosteroids.<br />

IS-OCP-MO 379 (5)<br />

Techniques in Orbital Decompression<br />

Morton Asa (1)<br />

1. Helps International and Caster Foundation<br />

Surgical techniques for orbital decompression will be reviewed. Medial, lateral<br />

and inferior orbital approaches, as well as the importance <strong>of</strong> fat removal will<br />

be discussed. The anatomy associated with the transcaruncular approach for<br />

medial orbital decompression will be reviewed.<br />

IS-OCP-MO 379 (6)<br />

Strabismus Correction in Thyroid Eye Disease<br />

Cockerham Kimberly (1)<br />

1. Cockerham Eye Consultants<br />

Management <strong>of</strong> dysmotility in thyroid eye disease. Management options <strong>of</strong><br />

double vision during active phase <strong>of</strong> thyroid eye disease<br />

a. Prisms<br />

b. Botox<br />

c. Nasonex<br />

d. Deposteroids<br />

e. Oral Steroids<br />

f. Intravenous Steroids<br />

g. External Beam Radiation<br />

h. Other immunomodulation<br />

During restrictive chronic phase <strong>of</strong> thyroid eye disease<br />

a. Resections<br />

b. Recessions with or without adjustable sutures<br />

c. Disinsertion<br />

367

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!